NeuroPace Inc.(NPCE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NPCE NeuroPace Inc.

Pre-Mkt 01-14 04:26:02 EST

16.13

-0.78

-4.61%

High17.90	Low15.74	Vol467.19K
Open17.75	D1 Closing16.91	Amplitude12.75%
Mkt Cap533.60M	Tradable Cap363.29M	Total Shares33.08M
T/O7.66M	T/O Rate2.07%	Tradable Shares22.52M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NPCE","market":"US","secType":"STK","nameCN":"NeuroPace Inc.","latestPrice":16.13,"timestamp":1768338000000,"preClose":16.91,"halted":0,"volume":467193,"delay":0,"floatShares":22522505,"shares":33081498,"eps":-0.753018,"marketStatus":"Pre-Mkt","change":-0.78,"latestTime":"01-14 04:26:02 EST","open":17.75,"high":17.896,"low":15.74,"amount":7664152.597626001,"amplitude":0.127499,"askPrice":17.67,"askSize":100,"bidPrice":14.77,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.753018,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1768401000000},"marketStatusCode":1,"adr":0,"listingDate":1619064000000,"exchange":"NASDAQ","adjPreClose":16.13,"postHourTrading":{"tag":"盘后","latestPrice":16.13,"preClose":16.13,"latestTime":"19:58 EST","volume":898,"amount":14488.12,"timestamp":1768352313160},"volumeRatio":1.0132719890462774,"impliedVol":0.1828,"impliedVolPercentile":0.032},"requestUrl":"/m/hq/s/NPCE/wiki","defaultTab":"wiki","newsList":[{"id":"2603681498","title":"NeuroPace sees FY26 revenue $98M-$100M, consensus $98.44M","url":"https://stock-news.laohu8.com/highlight/detail?id=2603681498","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603681498?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:41","pubTimestamp":1768308069,"startTime":"0","endTime":"0","summary":"The company said, “The Company currently anticipates 2026 total revenue of $98 million to $100 million, which contemplates growth of 20% to 22% for...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neuropace-sees-fy26-revenue-98m-100m-consensus-98-44m-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neuropace-sees-fy26-revenue-98m-100m-consensus-98-44m-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NPCE"],"gpt_icon":0},{"id":"2603897236","title":"NeuroPace reports preliminary Q4 revenue $26.6M, consensus $24.43M","url":"https://stock-news.laohu8.com/highlight/detail?id=2603897236","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603897236?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:35","pubTimestamp":1768307740,"startTime":"0","endTime":"0","summary":"Reports preliminary FY25 revenue $100M, consensus $97.78M. “2025 was an important year for NeuroPace (NPCE) as we delivered strong growth, strength...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neuropace-reports-preliminary-q4-revenue-26-6m-consensus-24-43m-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neuropace-reports-preliminary-q4-revenue-26-6m-consensus-24-43m-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NPCE"],"gpt_icon":0},{"id":"2603689125","title":"Neuropace Projects Up to $100 Million Revenue in 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2603689125","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603689125?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:31","pubTimestamp":1768307470,"startTime":"0","endTime":"0","summary":"NeuroPace Inc. has released its preliminary unaudited financial results for the fourth quarter and full year 2025, along with its initial outlook for 2026. The company expects total revenue for 2025 to be approximately $100 million, representing a 25% increase over 2024. Fourth quarter 2025 revenue is projected to be about $26.6 million, up 24% from the same period in 2024. RNS revenue for 2025 is anticipated to reach $81.7 million, a 25% year-over-year increase. Looking ahead to 2026, NeuroPace forecasts total revenue between $98 million and $100 million, reflecting 20% to 22% growth in core RNS revenue compared to preliminary 2025 results, excluding any contribution from idiopathic generalized epilepsy . The company expects first quarter 2026 revenue to be in the range of $21 million to $22 million. IGE is expected to contribute following potential approval in the second half of 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL5PF4Rq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4082","NPCE"],"gpt_icon":0},{"id":"2603689905","title":"Neuropace Inc - Expects FY 2025 Revenue of $100 Mln, up 25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603689905","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603689905?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:30","pubTimestamp":1768307401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUABQQ6XX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NPCE","BK4539"],"gpt_icon":0},{"id":"2603689454","title":"Neuropace Inc - Revenue for Q1 of 2026 Is Expected to Be Approximately $21 Mln to $22 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2603689454","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603689454?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:30","pubTimestamp":1768307401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUABQQ6XX:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4082","NPCE"],"gpt_icon":0},{"id":"2603689113","title":"Neuropace Inc - Ends Distribution Agreement With Dixi Medical","url":"https://stock-news.laohu8.com/highlight/detail?id=2603689113","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603689113?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:30","pubTimestamp":1768307401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUABQQ6XX:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4082","NPCE"],"gpt_icon":0},{"id":"2603668911","title":"Neuropace Inc - Ige Expected Following Potential Approval in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2603668911","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603668911?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:30","pubTimestamp":1768307401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUABQQ6XX:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","NPCE","BK4082"],"gpt_icon":0},{"id":"2603495689","title":"Neuropace Inc  FY2026 Shr View $-0.63, REV View $98.5 Mln -- Lseg Ibes Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2603495689","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603495689?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:30","pubTimestamp":1768307401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUABQQ6XX:9","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NPCE","BK4539","BK4082"],"gpt_icon":0},{"id":"2603168945","title":"Neuropace Inc - Currently Anticipates 2026 Total Revenue of $98 Mln to $100 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2603168945","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603168945?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:30","pubTimestamp":1768307401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUABQQ6XX:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4082","NPCE"],"gpt_icon":0},{"id":"2603896246","title":"Neuropace, Inc. Outlook FY Gross Margin 81-82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603896246","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603896246?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:30","pubTimestamp":1768307401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nPLXC91B98:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4082","NPCE"],"gpt_icon":0},{"id":"2592899091","title":"NeuroPace Submits FDA Application to Expand RNS System Indication for Drug-Resistant Epilepsy","url":"https://stock-news.laohu8.com/highlight/detail?id=2592899091","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592899091?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:00","pubTimestamp":1765976453,"startTime":"0","endTime":"0","summary":"NeuroPace, Inc. has filed a Premarket Approval Supplement  application with the U.S. Food and Drug Administration  seeking to expand the labeled indication for its RNS System to include patients with antiseizure-medication resistant idiopathic generalized epilepsy  with generalized tonic-clonic seizures. The submission is supported by positive preliminary 18-month data from the NAUTILUS clinical trial. The company aims to provide new treatment options for patients with drug-resistant IGE, who currently lack approved neuromodulation therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief via Business Wire  on December 17, 2025, and is solely responsible for","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL5xykKK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NPCE","BK4082","BK4539"],"gpt_icon":0},{"id":"2592990642","title":"Neuropace Files Pma Supplement to FDA Seeking Expanded Rns® System Indication for Idiopathic Generalized Epilepsy","url":"https://stock-news.laohu8.com/highlight/detail?id=2592990642","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592990642?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:00","pubTimestamp":1765976403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUAD8GPK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NPCE","BK4539"],"gpt_icon":0},{"id":"2591922935","title":"UBS Adjusts NeuroPace Price Target to $22 From $18, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2591922935","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591922935?lang=en_us&edition=fundamental","pubTime":"2025-12-16 23:50","pubTimestamp":1765900215,"startTime":"0","endTime":"0","summary":"NeuroPace (NPCE) has an average rating of Buy and mean price target of $19.25, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NPCE"],"gpt_icon":0},{"id":"2591168938","title":"NeuroPace Is Maintained at Buy by UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2591168938","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591168938?lang=en_us&edition=fundamental","pubTime":"2025-12-16 22:36","pubTimestamp":1765895760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NPCE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 16, 2025 09:36 ET (14:36 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NPCE"],"gpt_icon":0},{"id":"2590848539","title":"NeuroPace Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2590848539","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590848539?lang=en_us&edition=fundamental","pubTime":"2025-12-11 00:09","pubTimestamp":1765382940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NPCE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 10, 2025 11:09 ET (16:09 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NPCE"],"gpt_icon":0},{"id":"2589666353","title":"Neuropace Inc - 77% Median Reduction in Gtc Seizures at 18 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2589666353","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589666353?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:05","pubTimestamp":1765199116,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE0V8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","BK4539","NPCE"],"gpt_icon":0},{"id":"2589353667","title":"Neuropace: Remains on Track to Submit Nautilus Pma Supplement to FDA for Ige Indication Expansion by Year-End","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353667","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589353667?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:05","pubTimestamp":1765199116,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE0V8:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4082","NPCE"],"gpt_icon":0},{"id":"2589353664","title":"Neuropace Announces Positive 18-Month Nautilus Trial Results in Idiopathic Generalized Epilepsy","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353664","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589353664?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:05","pubTimestamp":1765199116,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE0V8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4082","NPCE"],"gpt_icon":0},{"id":"2589353324","title":"NeuroPace Reports Positive 18-Month Results from NAUTILUS Trial for Drug-Resistant Epilepsy","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353324","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589353324?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:01","pubTimestamp":1765198889,"startTime":"0","endTime":"0","summary":"NeuroPace, Inc. has announced the presentation of preliminary 18-month safety and effectiveness results from its ongoing NAUTILUS clinical trial at the American Epilepsy Society  meeting. The NAUTILUS trial is evaluating the RNS System as an adjunctive therapy for the treatment of antiseizure medication-resistant idiopathic generalized epilepsy  with generalized tonic-clonic  seizures. The RNS System is a brain-responsive device designed to deliver real-time, personalized treatment at the seizure source. Further details regarding the trial can be found on the NeuroPace website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief via Business Wire  on December 08,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL86lQMy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NPCE","BK4539","BK4082"],"gpt_icon":0},{"id":"2588053402","title":"Neuropace Unveils New Clinical Data and AI Tools for RNS System at AES 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2588053402","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588053402?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:02","pubTimestamp":1764680520,"startTime":"0","endTime":"0","summary":"NeuroPace Inc. has announced that new clinical data and advances related to its RNS System and AI-powered NeuroPace platform will be featured at the 2025 American Epilepsy Society  Annual Meeting in Atlanta, Georgia. The company will present new analyses from the RNS System Post-Approval Study , including long-term seizure reduction durability and quality-of-life outcomes in drug-resistant focal epilepsy populations. Preliminary 18-month safety and efficacy results from the NAUTILUS clinical trial, which evaluates responsive thalamic stimulation for idiopathic generalized epilepsy, will also be presented. In addition, NeuroPace will provide an initial overview of its next-generation AI and SeizureID tools, designed to enhance epilepsy care through advanced analysis of intracranial EEG data. These results and tools are scheduled to be presented at the upcoming AES 2025 meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL2z9Zcz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","NPCE","BK4539"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neuropace.com","stockEarnings":[{"period":"1week","weight":-0.0159},{"period":"1month","weight":-0.0037},{"period":"3month","weight":0.469},{"period":"6month","weight":0.7764},{"period":"1year","weight":0.332},{"period":"ytd","weight":0.0447}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":0.0176},{"period":"3month","weight":0.043},{"period":"6month","weight":0.1047},{"period":"1year","weight":0.1933},{"period":"ytd","weight":0.0174}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. The company's RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip leads and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.8,"avgChangeRate":0.526588},{"month":2,"riseRate":0.5,"avgChangeRate":0.027762},{"month":3,"riseRate":0.25,"avgChangeRate":-0.069398},{"month":4,"riseRate":0.25,"avgChangeRate":-0.001962},{"month":5,"riseRate":0.2,"avgChangeRate":-0.144641},{"month":6,"riseRate":0.6,"avgChangeRate":-0.044447},{"month":7,"riseRate":0.4,"avgChangeRate":-0.04203},{"month":8,"riseRate":0.6,"avgChangeRate":0.216975},{"month":9,"riseRate":0.4,"avgChangeRate":-0.065676},{"month":10,"riseRate":0,"avgChangeRate":-0.132059},{"month":11,"riseRate":0.6,"avgChangeRate":0.163487},{"month":12,"riseRate":0.6,"avgChangeRate":0.015944}],"exchange":"NASDAQ","name":"NeuroPace Inc.","nameEN":"NeuroPace Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NeuroPace Inc.(NPCE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NeuroPace Inc.(NPCE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NeuroPace Inc.,NPCE,NeuroPace Inc.股票,NeuroPace Inc.股票老虎,NeuroPace Inc.股票老虎国际,NeuroPace Inc.行情,NeuroPace Inc.股票行情,NeuroPace Inc.股价,NeuroPace Inc.股市,NeuroPace Inc.股票价格,NeuroPace Inc.股票交易,NeuroPace Inc.股票购买,NeuroPace Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NeuroPace Inc.(NPCE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NeuroPace Inc.(NPCE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}